“The vaccination against Herpes zoster was introduced in 2017 and is a vaccination with a high value both on a health, social and economic level, due to all the costs resulting from the complications of zoster. Unfortunately, coverage is not yet satisfactory in most Italian regions, as they are far from the coverage targets. We therefore still need to work a lot to go up.” Thus Carlo Signorelli, president of the National Technical Advisory Group on Vaccinations – Nitag, on the sidelines of the conference entitled “Staying healthy thanks to vaccination prevention in adults: the example of the Herpes Zoster vaccine”, organized with the support of GSK and first stage of the campaign promoted by the Longevitas Foundation, with the aim of improving people’s quality of life, optimizing and reducing health spending through the development of healthy longevity, allowing important savings to be reinvested in health.
The initiative, which took place today in the Sala Gonfalone of Palazzo Pirelli in Milan, was carried out under the patronage of the Lombardy Region and the Higher Institute of Health and with the support of GSK.
“I believe that it is necessary to consider the active call as an important element in order to increase vaccination coverage – adds Signorelli – Subsequently, each region must choose the areas in which to administer the vaccine: from the National Health Service clinics, to hospitals, to pharmacies. Veneto has already made the active call available, obtaining very favorable results”.
#Vaccines #Signorelli #Nitag #Herpes #zoster #vaccination #coverage #rate #satisfactory
